menu
    • menu

    Company profile for MicuRx Pharmaceuticals

    NEW Drugs in Dev: 4
    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

    Virtual Booth

    Contact Supplier

    Cosma S.p.A., part of CFM Group with AMSA & Clarochem, provides global pharma & veterinary health with 300+ tons of FDA-approved APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    MicuRx mission is to discover and develop safer and more convenient antibiotics to combat drug-resistant bacterial infections. Multi-drug resistant (MDR) infections represent a major global threat to the public health, routinely forcing the use of antibiotics with high incidence of adverse effects.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    MicuRx PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    3916 Trust Way Hayward, CA 94545
    Telephone
    Telephone
    (510) 782-2021
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.micurx.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/micurx-pharmaceuticals-inc-
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    SCOPE Summit

    SCOPE Summit

    Not Confirmed

    envelop Contact Supplier

    SCOPE Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    MicuRx Announces FDA Clearance of IND Application of MRX-5
    MicuRx Announces FDA Clearance of IND Application of MRX-5

    29 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/micurx-announces-fda-clearance-of-ind-application-to-proceed-to-phase-2a-trial-of-mrx-5-in-patients-with-mycobacterium-abscessus-pulmonary-disease-302673967.html

    PR NEWSWIRE
    29 Jan 2026
    Share Share
    MicuRx to Present 15 Studies at ESCMID Global 2025
    MicuRx to Present 15 Studies at ESCMID Global 2025

    08 Apr 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/micurx-15-clinical-and-preclinical-research-studies-to-be-presented-at-escmid-global-2025-302423147.html

    PR NEWSWIRE
    08 Apr 2025
    Share Share
    MicuRx Contezolid Ph 3 Trial Passes Safety Review For DFI Treatment
    MicuRx Contezolid Ph 3 Trial Passes Safety Review For DFI Treatment

    25 Feb 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/micurx-pharmaceutical-contezolid-global-phase-iii-clinical-trial-safety-and-efficacy-evaluation-endorsed-by-data-monitoring-committee-promising-prospects-for-diabetic-foot-infection-treatment-302384542.html

    PR NEWSWIRE
    25 Feb 2025
    Share Share
    FDA Grants Orphan Drug Designation to MicuRx for NTM Infections
    FDA Grants Orphan Drug Designation to MicuRx for NTM Infections

    02 Jan 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/fda-grants-orphan-drug-designation-to-micurxs-mrx-5-for-ntm-infections-302341089.html

    PR NEWSWIRE
    02 Jan 2025
    Share Share
    MicuRx Successfully Completes Ph 3 Trial Of MRX-4 For Injection
    MicuRx Successfully Completes Ph 3 Trial Of MRX-4 For Injection

    29 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/micurx-successfully-completes-phase-iii-clinical-trial-of-mrx-4-for-injection-in-china-302318196.html

    PR NEWSWIRE
    29 Nov 2024
    Share Share
    MicuRx Completes Phase 1 Trial of MRX-5 in Australia
    MicuRx Completes Phase 1 Trial of MRX-5 in Australia

    25 Oct 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/micurx-announces-the-successful-completion-of-phase-1-clinical-trial-of-mrx-5-in-australia-302287217.html

    PR NEWSWIRE
    25 Oct 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search